Steve Averbuch

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.2K citations · Full text

Cancer Immunosurveillance, Advanced Lung Disease, Medicine +8

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 762 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

Joan Albanell, Federico Rojo, Steve Averbuch et al. · Journal of Clinical Oncology · 2002 · 253 citations

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Judit Anido, Pablo Matar, Joan Albanell et al. · PubMed · 2003 · 248 citations

Anti-EGF receptor therapy

G. Blackledge, Steve Averbuch, Andrea Kay et al. · Prostate Cancer and Prostatic Diseases · 2000 · 18 citations

Medicine, Pharmacotherapy, Pharmacology +3